News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

International Wex Technologies (WXI): Tectin(TM) Phase II Trial Begins In China



10/19/2005 5:11:27 PM

International Wex Technologies Inc. (TSX:WXI) (the "Company") is pleased to announce that the Tectin(TM) Phase II clinical trial in China has commenced to demonstrate the analgesic efficacy of Tectin(TM) in patients with chronic cancer pain. This is an efficacy trial in which an initial phase of escalating dose to the effective dose (Part I) is followed by a controlled phase (Part II). The total participants for Part I and Part II are approximately 300 patients, and will involve up to 8 SFDA (State Food and Drug Administration) authorized centers across China.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES